类风湿关节炎患者接受托珠单抗/沙利鲁单抗、阿巴西普和利妥昔单抗治疗的癌症风险:一项丹麦队列研究
基于丹麦全国登记数据的队列研究纳入21982次治疗启动、96475人年和1423例癌症,比较托珠单抗/沙利鲁单抗、阿巴西普或利妥昔单抗与TNF抑制剂及未使用bDMARD的RA患者的癌症风险。结果显示上述治疗组总体癌症风险未显著升高(HR范围0.7-1.1);阿巴西普暴露超过5年对比TNF抑制剂HR 1.41(95%CI 0.74-2.71),利妥昔单抗血液系统癌症风险非显著降低。
要点
- 托珠单抗/沙利鲁单抗、阿巴西普或利妥昔单抗治疗组总体癌症风险较TNF抑制剂和bDMARD初治患者未显著升高(HR范围0.7-1.1)。
- 阿巴西普暴露超过5年对比TNF抑制剂HR 1.41(95%CI 0.74-2.71),差异未达统计学显著。
- 利妥昔单抗血液系统癌症风险对比TNF抑制剂HR 0.09(95%CI 0.00-2.06)、对比bDMARD初治HR 0.13(95%CI 0.00-1.89),均未达统计学显著。
核心结论
- 在真实世界环境中,RA患者接受托珠单抗/沙利鲁单抗、阿巴西普或利妥昔单抗治疗,与接受TNF抑制剂治疗及未使用bDMARD的RA患者相比,未增加癌症风险。
研究设计与样本
- 基于丹麦全国登记数据的队列研究,纳入2006年至2020年启动bDMARD治疗(托珠单抗/沙利鲁单抗、阿巴西普、利妥昔单抗、TNF抑制剂)的RA患者,以及启动第二种传统合成DMARD的bDMARD初治RA患者;患者可贡献多次治疗,按「最新治疗类型」方式分配人年、死亡和癌症;采用逆概率治疗加权和加权病因特异性Cox模型计算癌症风险比(HR)。
- 共识别21982次治疗启动、96475人年和1423例癌症。
主要发现
- 托珠单抗/沙利鲁单抗、阿巴西普或利妥昔单抗治疗组总体癌症风险较TNF抑制剂和bDMARD初治组均未显著升高,HR范围0.7-1.1。
- 阿巴西普暴露超过5年对比TNF抑制剂HR 1.41(95%CI 0.74-2.71),差异未达统计学显著。
- 利妥昔单抗治疗血液系统癌症风险对比TNF抑制剂HR 0.09(95%CI 0.00-2.06),对比bDMARD初治HR 0.13(95%CI 0.00-1.89),均未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate cancer risk in RA patients treated with tocilizumab/sarilumab, abatacept or rituximab compared with those who received TNF inhibitors (TNFi) and compared with biological DMARDs (bDMARD)-naïve RA patients. METHODS: Nationwide registry-based cohort study of RA patients who initiated bDMARD treatment with tocilizumab/sarilumab, abatacept, rituximab, and TNFi, as well as bDMARD-naive patients who initiated their second type of conventional synthetic DMARD. Patients were identified in the Danish Rheumatology Quality Register (DANBIO) and followed for cancer from 2006 to 2020. Patients could contribute multiple treatments, with person years, deaths and cancers allocated to each treatment group in a 'latest type of treatment' manner. Inverse probability of treatment weighting and weighted cause-specific Cox models were used to calculate hazard ratios (HRs) for cancer in each tocilizumab/sarilumab, abatacept and rituximab group compared with TNFi-treated and bDMARD-naïve groups, respectively. RESULTS: In total, 21 982 treatment initiations, 96 475 person years and 1423 cancers were identified. There were no statistically significant increased HRs for overall cancer in tocilizumab/sarilumab, abatacept or rituximab treatment groups (HRs ranged from 0.7 to 1.1). More than 5 years of abatacept exposure showed a non-significantly increased HR compared with TNFi (HR 1.41, 95% CI 0.74-2.71). For haematological cancers, rituximab treatment showed non-significantly reduced HRs: vs TNFi-treated (HR 0.09; 95% CI 0.00-2.06) and bDMARD-naïve (HR 0.13; 95% CI 0.00-1.89). CONCLUSION: Treatment with tocilizumab/sarilumab, abatacept or rituximab in RA patients was not associated with increased risks of cancer compared with TNFi-treated and with bDMARD-naïve RA patients in a real-world setting.
引用
- Westermann R, Cordtz RL, Duch K, et al. Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study. Rheumatology (Oxford). 2025. PMID: 38452297. doi:10.1093/rheumatology/keae140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。